To investigate the efficacy of
Taxanes- and
Oxaliplatin-based
chemotherapies (TC and OC) in the treatment of
gastric cancer patients after D2
gastrectomy with different Lauren types. In this study, 299 patients of gastric
adenocarcinoma with D2
lymph node dissection were reviewed between 2007 and 2014.
Chemotherapies were classified as
Oxaliplatin-based and
Taxanes-based regimen. Treatment outcomes were analyzed according to different Lauren types, such as the intestinal type, diffuse type, and mixed type groups, respectively. The disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test was used for univariate analysis, and Cox regression was used for multivariate analysis. In diffuse type
gastric cancer, the
Oxaliplatin-based arm had a longer median DFS and OS compared with
Taxanes-based arm (DFS: 47.0 vs 28.6 months, P = 0.04; OS: 51.9 vs 34.5 months, P = 0.048). The
chemotherapy regimen was an independent prognostic factor for DFS and OS of diffuse type
gastric cancer patients by multivariate analysis (P = 0.01). In the intestinal type, although the DFS and OS of intestinal type patients in TC group were higher than those in OC group (DFS: 53.4 vs 42.4 months; OS: 69.7 vs 57.8 months), there was no statistical significance observed (both P > 0.05). For the mixed type, the 2 different
chemotherapy regimens achieved similar median DFS and OS. In a conclusion, the patients of diffuse type were more sensitive to OC, and the intestinal type patients may be benefit from TC. Therefore, it will be of benefit for gastric patients by introducing Lauren classification clinically and to help the choice of
chemotherapy regimen for gastric patients after D2
gastrectomy.